Current Advances Toward the Encapsulation of Cas9

Area of Science:

• Biotechnology
• Genetics
• Nanomedicine

Background:

• Genetic diseases pose significant challenges to patient quality of life.
• Current treatments often manage symptoms rather than address the root cause.
• Clustered regularly short palindromic repeat (CRISPR)-associated protein 9 (Cas9) offers a potential solution for genetic disease treatment.

Purpose of the Study:

• To review current advances in encapsulating and delivering Cas9 using nanoparticles.
• To identify key factors and challenges in developing effective Cas9 delivery systems.
• To highlight considerations for optimizing Cas9 function and delivery for gene editing.

Main Methods:

• Overview of current literature on nanoparticle-based delivery of Cas9.
• Analysis of lipid- and polymer-based nanoparticles as potential delivery vehicles.
• Discussion of factors influencing Cas9 system effectiveness, including material selection and charge interactions.

Main Results:

• Nanoparticles are identified as an ideal delivery method for Cas9 due to size, modifiable charge, and adaptability.
• Lipid nanoparticles are currently more advanced in clinical application than polymer-based ones.
• Cationic lipid/polymer-based nanoparticle systems show the most promise for Cas9 delivery.

Conclusions:

• Further research is needed to understand optimal internal environments for Cas9 function.
• Addressing charge interactions between Cas9, co-delivered molecules, and nanoparticles is crucial.
• Development of translatable, polymer-based delivery vehicles for Cas9 holds significant therapeutic potential.